What is the share price of Sanjivani Paranteral Ltd (SANJIVIN) today?
The share price of SANJIVIN as on 27th July 2026 is ₹151.75. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Sanjivani Paranteral Ltd (SANJIVIN) share?
The past returns of Sanjivani Paranteral Ltd (SANJIVIN) share are- Past 1 week: 8.39%
- Past 1 month: 4.66%
- Past 3 months: -10.09%
- Past 6 months: -18.17%
- Past 1 year: -32.62%
- Past 3 years: 113.02%
- Past 5 years: 414.38%
What are the peers or stocks similar to Sanjivani Paranteral Ltd (SANJIVIN)?
The peers or stocks similar to Sanjivani Paranteral Ltd (SANJIVIN) include:What is the market cap of Sanjivani Paranteral Ltd (SANJIVIN) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sanjivani Paranteral Ltd (SANJIVIN) is ₹184.51 Cr as of 27th July 2026.What is the 52 week high and low of Sanjivani Paranteral Ltd (SANJIVIN) share?
The 52-week high of Sanjivani Paranteral Ltd (SANJIVIN) is ₹268.80 and the 52-week low is ₹126.What is the PE and PB ratio of Sanjivani Paranteral Ltd (SANJIVIN) stock?
The P/E (price-to-earnings) ratio of Sanjivani Paranteral Ltd (SANJIVIN) is 27.58. The P/B (price-to-book) ratio is 4.63.Which sector does Sanjivani Paranteral Ltd (SANJIVIN) belong to?
Sanjivani Paranteral Ltd (SANJIVIN) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Sanjivani Paranteral Ltd (SANJIVIN) shares?
You can directly buy Sanjivani Paranteral Ltd (SANJIVIN) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Sanjivani Paranteral Ltd
SANJIVIN Share Price
BSE₹151.752.09% (+3.10)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
SANJIVIN Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
SANJIVIN Performance & Key Metrics
SANJIVIN Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 27.54 | 4.63 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 45.27 | 5.97 | 0.52% |
SANJIVIN Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
SANJIVIN Company Profile
Sanjivani Paranteral is engaged in the business of pharmaceutical products.
SUNPHARMA
PE Ratio
41.25
41.25
1Y Return
15.95%
15.95%
Buy Reco %
93.75
93.75
TORNTPHARM
PE Ratio
88.25
88.25
1Y Return
38.55%
38.55%
Buy Reco %
78.57
78.57
CIPLA
PE Ratio
29.35
29.35
1Y Return
10.34%
10.34%
Buy Reco %
63.89
63.89
ZYDUSLIFE
PE Ratio
21.93
21.93
1Y Return
13.07%
13.07%
Buy Reco %
55.17
55.17
LUPIN
PE Ratio
20.66
20.66
1Y Return
22.93%
22.93%
Buy Reco %
55.56
55.56
SANJIVIN Sentiment Analysis
SANJIVIN Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
SANJIVIN Stock Summary · May 2026
Management framed FY'26 as a transition year and positioned FY'27 as a scale‑up phase, reporting consolidated Q4 revenue of INR 132.1 million and targeting base‑business revenue of INR 80–85 crore for FY'27. Leadership emphasized execution of a multi‑vertical strategy—expanding injectables, IV fluids and nutraceuticals through joint ventures and recent capacity additions—while highlighting early commercial traction from the new IV line and a ramping European nutraceutical JV. They struck a constructive, execution‑focused tone but acknowledged clear tensions: heavy export dependence combined with late‑February/March shipping disruptions materially reduced Q4 shipments, and near‑term input‑cost and packaging pressures have required elevated inventories and higher freight. Management described mitigation steps taken (alternative routing, supplier diversification, partial freight reimbursement) and noted receivables have shortened, improving working capital. Regulatory approvals remain a gating factor for commercial scale‑up and were delayed in some cases, but management said approvals and export execution should improve and they expect export revenues to recover in Q1 FY'27 as the company pursues the annual targets.
SANJIVIN Stock Growth Drivers
SANJIVIN Stock Growth Drivers
6Established, quality‑focused manufacturing and broad export footprint
The company is a WHO GMP–certified manufacturer with over 25 years of injectable and oral‑dosage
Strategic diversification into multiple verticals with early commercialization success
Management has shifted the business model from a single‑engine to a multi‑vertical platform, executing joint
SANJIVIN Stock Challenges
SANJIVIN Stock Challenges
6Logistics and supply‑chain disruptions causing lost exports and operational uncertainty
Geopolitical tensions at the end of February disrupted shipping routes, container availability and cargo handling
Margin compression from higher input and logistics costs combined with lower operating leverage
A combination of increased raw‑material and packing costs in March 2026, elevated freight from rerouted
SANJIVIN Forecast
SANJIVIN Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
SANJIVIN
SANJIVIN
Income
Balance Sheet
Cash Flow
Quarterly Normal View
SANJIVIN Income Statement
SANJIVIN Income Statement
Quarterly Normal View
| Quarter | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 15.22 | 12.92 | 16.52 | 18.52 | 17.66 | 18.61 | 17.93 | 15.66 | 22.36 | 13.81 | ||||||||||
Operating & Other expenses | 13.00 | 10.71 | 14.10 | 15.28 | 14.80 | 15.57 | 15.24 | 13.25 | 18.22 | 11.64 | ||||||||||
EBITDA | 2.22 | 2.21 | 2.42 | 3.24 | 2.86 | 3.04 | 2.69 | 2.41 | 4.14 | 2.17 | ||||||||||
| Depreciation/Amortization | 0.24 | 0.24 | 0.13 | 0.15 | 0.16 | 0.18 | 0.16 | 0.17 | 0.23 | 0.66 | ||||||||||
| PBIT | 1.98 | 1.97 | 2.29 | 3.09 | 2.70 | 2.86 | 2.53 | 2.24 | 3.91 | 1.51 | ||||||||||
| Interest & Other Items | 0.08 | 0.09 | 0.02 | 0.18 | 0.19 | 0.20 | 0.22 | 0.05 | 0.21 | 0.31 | ||||||||||
| PBT | 1.90 | 1.88 | 2.27 | 2.91 | 2.51 | 2.66 | 2.31 | 2.19 | 3.70 | 1.20 | ||||||||||
| Taxes & Other Items | 0.25 | 0.63 | 0.56 | 0.62 | 0.61 | 0.46 | 0.57 | 0.55 | 0.92 | 0.66 | ||||||||||
| Net Income | 1.65 | 1.25 | 1.71 | 2.29 | 1.90 | 2.20 | 1.74 | 1.64 | 2.78 | 0.54 | ||||||||||
| EPS | 1.65 | 1.08 | 1.47 | 1.96 | 1.62 | 1.84 | 1.46 | 1.33 | 2.21 | 0.49 |
SANJIVIN Company Updates
SANJIVIN Stock Peers
SANJIVIN Past Performance & Peer Comparison
SANJIVIN Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Sanjivani Paranteral Ltd | 27.58 | 4.63 | — |
| Sun Pharmaceutical Industries Ltd | 41.25 | 5.65 | 0.81% |
| Torrent Pharmaceuticals Ltd | 88.25 | 10.86 | 0.67% |
| Cipla Ltd | 29.35 | 3.30 | 0.92% |
SANJIVIN Stock Price Comparison
Compare SANJIVIN with any stock or ETFCompare SANJIVIN with any stock or ETF
SANJIVIN
SANJIVIN Holdings
SANJIVIN Shareholdings
SANJIVIN Promoter Holdings Trend
SANJIVIN Promoter Holdings Trend
SANJIVIN Institutional Holdings Trend
SANJIVIN Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
SANJIVIN Shareholding Pattern
SANJIVIN Shareholding Pattern
SANJIVIN Shareholding History
SANJIVIN Shareholding History
Foreign Institutions
smallcases containing SANJIVIN stock
smallcases containing SANJIVIN stock
Looks like this stock is not in any smallcase yet.
SANJIVIN Events
SANJIVIN Events
SANJIVIN Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
SANJIVIN has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
SANJIVIN Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
SANJIVIN has not given any dividends in last 5 years
SANJIVIN Upcoming Dividends
SANJIVIN Upcoming Dividends
No upcoming dividends are available
SANJIVIN Past Dividends
SANJIVIN Past Dividends
Cash Dividend
Ex DateEx DateSep 19, 2025
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Sep 19, 2025
SANJIVIN Stock News & Opinions
SANJIVIN Stock News & Opinions
Articles & Videos
Corporate
Corporate
Sanjivani Paranteral to convene board meetingSanjivani Paranteral will hold a meeting of the Board of Directors of the Company on 23 July 2026.
6 days agoCapital Market - Live
Corporate
Corporate
Sanjivani Paranteral to hold board meetingSanjivani Paranteral will hold a meeting of the Board of Directors of the Company on 21 May 2026.
2 months agoCapital Market - Live
Earnings
Earnings
Sanjivani Paranteral consolidated net profit declines 74.89% in the March 2026 quarterNet profit of Sanjivani Paranteral declined 74.89% to Rs 0.55 crore in the quarter ended March 2026 as against Rs 2.19 crore during the previous quarter ended March 2025. Sales declined 27.34% to Rs 13.21 crore in the quarter ended March 2026 as against Rs 18.18 crore during the previous quarter ended March 2025. For the full year,net profit declined 17.31% to Rs 6.69 crore in the year ended March 2026 as against Rs 8.09 crore during the previous year ended March 2025. Sales declined 2.04% to Rs 68.67 crore in the year ended March 2026 as against Rs 70.10 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales13.2118.18 -27 68.6770.10 -2 OPM %11.8814.36 -15.0114.76 - PBDT1.862.84 -35 10.6110.97 -3 PBT1.202.65 -55 9.3910.35 -9 NP0.552.19 -75 6.698.09 -17 Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Corporate
Sanjivani Paranteral schedules board meetingSanjivani Paranteral will hold a meeting of the Board of Directors of the Company on 14 May 2026.
2 months agoCapital Market - Live
Earnings
Earnings
Sanjivani Paranteral consolidated net profit rises 46.32% in the December 2025 quarterNet profit of Sanjivani Paranteral rose 46.32% to Rs 2.78 crore in the quarter ended December 2025 as against Rs 1.90 crore during the previous quarter ended December 2024. Sales rose 27.15% to Rs 22.06 crore in the quarter ended December 2025 as against Rs 17.35 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales22.0617.35 27 OPM %17.3614.70 - PBDT3.932.67 47 PBT3.702.51 47 NP2.781.90 46 Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Corporate
Sanjivani Paranteral to announce Quarterly ResultSanjivani Paranteral will hold a meeting of the Board of Directors of the Company on 13 February 2026.Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Earnings
Sanjivani Paranteral consolidated net profit declines 28.70% in the September 2025 quarterNet profit of Sanjivani Paranteral declined 28.70% to Rs 1.64 crore in the quarter ended September 2025 as against Rs 2.30 crore during the previous quarter ended September 2024. Sales declined 14.51% to Rs 15.50 crore in the quarter ended September 2025 as against Rs 18.13 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales15.5018.13 -15 OPM %14.5215.72 - PBDT2.363.06 -23 PBT2.192.92 -25 NP1.642.30 -29 Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Corporate
Sanjivani Paranteral announces board meeting dateSanjivani Paranteral will hold a meeting of the Board of Directors of the Company on 14 November 2025.Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Corporate
Sanjivani Paranteral schedules AGMSanjivani Paranteral announced that the 31th Annual General Meeting(AGM) of the company will be held on 26 September 2025.Powered by Capital Market - Live
11 months agoCapital Market - Live
Earnings
Earnings
Sanjivani Paranteral consolidated net profit rises 1.17% in the June 2025 quarterNet profit of Sanjivani Paranteral rose 1.17% to Rs 1.73 crore in the quarter ended June 2025 as against Rs 1.71 crore during the previous quarter ended June 2024. Sales rose 8.82% to Rs 17.89 crore in the quarter ended June 2025 as against Rs 16.44 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales17.8916.44 9 OPM %14.7614.17 - PBDT2.462.41 2 PBT2.302.27 1 NP1.731.71 1 Powered by Capital Market - Live
11 months agoCapital Market - Live
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant